Veronika Tchesnokova1, Kim Riddell2, Delia Scholes3, James R Johnson4, Evgeni V Sokurenko1,5. 1. Department of Microbiology, University of Washington School of Medicine, Seattle. 2. Kaiser Permanente Washington, Seattle. 3. Kaiser Permanente Washington Health Research Institute, Seattle. 4. Veterans Affairs Medical Center and University of Minnesota, Minneapolis. 5. ID Genomics, Inc, Seattle, Washington.
Abstract
BACKGROUND: The pandemic spread of antibiotic resistance increases the likelihood of ineffective empirical therapy. The recently emerged fluoroquinolone-resistant Escherichia coli sequence type (ST) 131-H30R subclone (H30) is a leading cause of multidrug-resistant urinary tract infection (UTI) and bloodstream infection worldwide. METHODS: We studied the relative impact of H30 on the likelihood that bacteria isolated from urine of urgent care patients would be resistant to the empirically prescribed antibiotic regimen for UTI. RESULTS: Of 750 urinalysis-positive urine samples from urgent care patients with suspected UTI, 306 (41%) yielded E. coli, from 35 different clonal groups (clonotypes). H30 predominated (14% prevalence overall), especially among older patients (age ≥70 years: 26%) and those with diabetes (43%) or urinary catheterization (60%). Resistance to the empirically selected antibiotic regimen occurred in 16% (40/246) of patients overall, 28% (20/71) of older patients, 30% (8/27) of patients with diabetes, 60% (3/5) of catheterized patients, and 71% (22/30) of those with H30. H30's contribution to such mismatched antibiotic selection was 55% overall, 70% among older patients, and 100% among patients with diabetes or a urinary catheter. Among patients with ≥2 of these factors (older age, diabetes, or urinary catheter), 24% of all urinalysis-positive urine samples yielded H30, with a 92% likelihood of resistance to the selected empirical therapy. CONCLUSIONS: The multidrug-resistant H30 subclone of E. coli ST131 is responsible for the great majority of mismatched empirical antibiotic prescriptions for suspected UTI at an urgent care clinic among patients ≥70 years old or with diabetes or urinary catheterization. Published by Oxford University Press for the Infectious Diseases Society of America 2018.
BACKGROUND: The pandemic spread of antibiotic resistance increases the likelihood of ineffective empirical therapy. The recently emerged fluoroquinolone-resistant Escherichia coli sequence type (ST) 131-H30R subclone (H30) is a leading cause of multidrug-resistant urinary tract infection (UTI) and bloodstream infection worldwide. METHODS: We studied the relative impact of H30 on the likelihood that bacteria isolated from urine of urgent care patients would be resistant to the empirically prescribed antibiotic regimen for UTI. RESULTS: Of 750 urinalysis-positive urine samples from urgent care patients with suspected UTI, 306 (41%) yielded E. coli, from 35 different clonal groups (clonotypes). H30 predominated (14% prevalence overall), especially among older patients (age ≥70 years: 26%) and those with diabetes (43%) or urinary catheterization (60%). Resistance to the empirically selected antibiotic regimen occurred in 16% (40/246) of patients overall, 28% (20/71) of older patients, 30% (8/27) of patients with diabetes, 60% (3/5) of catheterized patients, and 71% (22/30) of those with H30. H30's contribution to such mismatched antibiotic selection was 55% overall, 70% among older patients, and 100% among patients with diabetes or a urinary catheter. Among patients with ≥2 of these factors (older age, diabetes, or urinary catheter), 24% of all urinalysis-positive urine samples yielded H30, with a 92% likelihood of resistance to the selected empirical therapy. CONCLUSIONS: The multidrug-resistant H30 subclone of E. coli ST131 is responsible for the great majority of mismatched empirical antibiotic prescriptions for suspected UTI at an urgent care clinic among patients ≥70 years old or with diabetes or urinary catheterization. Published by Oxford University Press for the Infectious Diseases Society of America 2018.
Authors: Veronika L Tchesnokova; Linda L Ottley; Kyoko Sakamoto; Joshua Fierer; Evgeni Sokurenko; Michael A Liss Journal: Urology Date: 2015-08-20 Impact factor: 2.649
Authors: Lauri A Hicks; Monina G Bartoces; Rebecca M Roberts; Katie J Suda; Robert J Hunkler; Thomas H Taylor; Stephanie J Schrag Journal: Clin Infect Dis Date: 2015-03-05 Impact factor: 9.079
Authors: James R Johnson; Paul Thuras; Brian D Johnston; Scott J Weissman; Ajit P Limaye; Kim Riddell; Delia Scholes; Veronika Tchesnokova; Evgeni Sokurenko Journal: Clin Infect Dis Date: 2016-03-29 Impact factor: 9.079
Authors: Miwako Kobayashi; Daniel J Shapiro; Adam L Hersh; Guillermo V Sanchez; Lauri A Hicks Journal: Open Forum Infect Dis Date: 2016-08-02 Impact factor: 3.835
Authors: James R Johnson; Brian D Johnston; Stephen B Porter; Connie Clabots; Tricia L Bender; Paul Thuras; Darren J Trott; Rowland Cobbold; Joanne Mollinger; Patricia Ferrieri; Sarah Drawz; Ritu Banerjee Journal: J Clin Microbiol Date: 2019-04-26 Impact factor: 5.948
Authors: Cara L Grimes; Ethan M Balk; Catrina C Crisp; Danielle D Antosh; Miles Murphy; Gabriela E Halder; Peter C Jeppson; Emily E Weber LeBrun; Sonali Raman; Shunaha Kim-Fine; Cheryl Iglesia; Alexis A Dieter; Ladin Yurteri-Kaplan; Gaelen Adam; Kate V Meriwether Journal: Int Urogynecol J Date: 2020-04-27 Impact factor: 2.894
Authors: Irene Merino; Stephen B Porter; Brian Johnston; Connie Clabots; Paul Thuras; Patricia Ruiz-Garbajosa; Rafael Cantón; James R Johnson Journal: Virulence Date: 2020-12 Impact factor: 5.882